Claudia Berenice Gil

Ms. Claudia Berenice Gil

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2024 in Differentiation
Verified
Journal Article
Closed access
NRNayeli G. Reyes-Nava
Nayeli G. Reyes-Nava
DPDavid Paz
David Paz
BPBriana E. Pinales
Briana E. Pinales
IPIsaiah Perez
Isaiah Perez
CGClaudia Berenice Gil
Claudia Berenice Gil
AQAnita M Quintana
Anita M Quintana

25 December 2025 in Journal of Developmental Biology
Verified
Journal Article
Open access
PDF file
CGClaudia Berenice Gil
Claudia Berenice Gil
DPDavid Paz
David Paz
BPBriana Elise Pinales
Briana Elise Pinales
VCVictoria L. Castro
Victoria L. Castro
CPClaire E. Perucho
Claire E. Perucho
AQAnita M Quintana
Anita M Quintana
Mutations in the transcriptional co-factor HCFC1 cause methylmalonic aciduria and homocystinemia, cblX type (cblX) (MIM#309541), non-syndromic X-linked intellectual disability (XLID), and focal epilepsy. Zebrafish studies have revealed increased activation of the Akt/mTor signaling pathway after mutation of hcfc1a, one ortholog of HCFC1. mTOR hyperactivation is linked to seizures, and its inhibition alleviates epilepsy in other preclinical models. We hypothesized that mTor overactivity in hcfc1a mutant zebrafish increases seizure susceptibility and/or severity. We employed a two-concentration model of the seizure-inducing agent, pentylenetetrazol (PTZ), with or without pretreatment of the mTor inhibitor, torin1. Mutation of hcfc1a did not alter the response to PTZ at sub-optimal concentrations, and the pharmaceutical inhibition of mTor using the compound Torin1 reduced response to 1 µM PTZ, but only in a dose-dependent manner. Higher doses of mTor inhibition did not reduce the seizure response in mutant larvae but were effective in wildtype siblings. These data suggest that inhibition of mTor in an hcfc1a-deficient background leads to a reaction that differs from the traditional response observed in wildtype siblings. Collectively, we present a model that can be used to test dose–response and the development of combinatorial treatment approaches in a high-throughput manner.